Pharmacokinetic and pharmacodynamic properties of the novel Basal Insulin Fc (BIF, insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes mellitus.

BIF was well-tolerated and the PK/PD profile enabled once-weekly dosing with minimal variation in exposure in a treatment interval of one week. The findings suggest BIF is suitable for further development as a weekly basal insulin in people with diabetes. This article is protected by copyright. All rights reserved.